ASX & Press Releases

Wednesday, June 10, 2015

Alchemia announced an update on its strategic initiatives to cut costs, divest assets and maximise revenues from its FDA approved drug fondaparinux.

Wednesday, June 10, 2015

Alchemia announced the retirements of Mr Santo Costa, Chairman, and Dr Susan Kelley, non-executive director and Chairman of Alchemia's Science and Technology Committee from its board of directors. Both retirements are effective immediately on June 10 2015.

Friday, May 29, 2015

Alchemia reported revenues of A$1.25m (US$0.98m) from its share of net profit of US-only sales of the generic anti-coagulant drug fondaparinux, marketed and sold by Dr. Reddy's Laboratories Limited for the quarter ending 31 March 2015.

Thursday, January 29, 2015

Alchemia announced today an update on its ongoing corporate and clinical review which commenced in October 2014 following the Phase III trial results for HA-Irinotecan in metastatic colorectal cancer (mCRC).

Wednesday, December 31, 2014

Alchemia announced today it has received a cash refund of $6.5m under the Australian Government’s R&D Tax Incentive Program. These funds were received as a result of a successful claim under the Australian R&D Tax Incentive Program for the year ending 30 June 2014.

Tuesday, December 9, 2014

Alchemia announced the appointment of Evolution Life Science Partners (Evolution), a division of Gordian Investments, LLC, FINRA registered broker-dealer, to assist with the execution of a strategic transaction for the Company’s VAST technology platform.

Thursday, November 27, 2014

Alchemia today reported profit share of A$2.02m (US$1.75m) on sales of its generic anti-coagulant drug fondaparinux for the quarter ending 30 September 2014.

Tuesday, November 11, 2014

Alchemia announced the departure of Thomas Liquard as Chief Executive Officer.
In the interim, Dr. Tracie Ramsdale, current Non-Executive Director and former Chief Executive Officer of Alchemia, will be assuming an Executive Director role to help Alchemia during this transition.
Alchemia thanks Mr. Liquard for his efforts on behalf of the company and wishes him well for the future.

Monday, November 10, 2014

Alchemia Annual General Meeting Chairman’s Address to Shareholders

Monday, November 10, 2014

Alchemia Limited announces that at today’s Annual General Meeting all Resolution Items put to Shareholders were passed unanimously on a show of hands.

Pages